Rena Buckstein, MD, FRCP, Odette Cancer Research Program, Sunnybrook Health Sciences Centre, Toronto, Canada, discusses Canada’s clinical research priorities and future plans for myelodysplastic syndromes (MDS). Dr Buckstein highlights findings from the Canadian MDS Registry, participation in the myeloMATCH screening study (NCT05564390), and emerging investigator-initiated trials exploring supportive care, transfusion management, and novel treatment strategies. This presentation took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, DC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.